Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical <sup>177</sup>Lu-DOTA-PSMA.

导出 LinkOut

翻译打印收藏纠错

第一作者： V K,Tishchenko

第一单位： A. F. Tsyb Medical Radiological Research Center - Affiliated Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Obninsk, Russia. vikshir82@mail.ru.

作者： V K,Tishchenko ^[1] ; O P,Vlasova ^[2] ; A A,Lebedeva ^[3] ; A V,Fedorova ^[2] ; A A,Pankratov ^[2] ; N B,Morozova ^[4] ; K A,Kuzenkova ^[4] ; E D,Stepchenkova ^[2] ; P V,Shegai ^[2] ; S A,Ivanov ^[2] ; A D,Kaprin ^[3]

作者单位： A. F. Tsyb Medical Radiological Research Center - Affiliated Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Obninsk, Russia. vikshir82@mail.ru. ^[1] A. F. Tsyb Medical Radiological Research Center - Affiliated Branch of the National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Obninsk, Russia. ^[2] National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Obninsk, Russia. ^[3] P. A. Gertsen Moscow Research Oncological Institute - Branch of National Medical Research Radiological Center, Ministry of Health of the Russian Federation, Moscow, Russia. ^[4] Patrice Lumumba Peoples' Friendship University of Russia, RUDN University), Moscow, Russia. ^[5]

关键词 lutetium-177 metastatic castrate-resistant prostate cancer prostate-specific membrane antigen radioligand therapy radiopharmaceutical